Grifols continues to lead initiatives to combat COVID-19 with the development of the first specific drug
- Grifols has become the first company to start production of an anti-SARS-CoV-2 hyperimmune immunoglobulin by leveraging its broad expertise and experience in the development of specific immunoglobulins used in the treatment and prevention of infections and that have been applied to healthcare emergencies like the Ebola outbreak
- Grifols is a worldwide leader in the production and sale of immunoglobulins, a plasma protein with proven safety, broad clinical applications and significant therapeutic potential
- Immunoglobulin therapies are mainly used to prevent and treat infections in cases of accidental exposure to infectious agents, primary and secondary immunodeficiencies, neurological conditions associated with autoimmune diseases, and weakened immune systems from cancer treatments
PR Newswire
BARCELONA, Spain, June 11, 2020
